Oral doxercalciferol therapy forsecondary hyperparathyroidismin a peritoneal dialysis patient

Sm, Sprague; Lt, Ho

doi:10.5414/cnp58155

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, subsequent pharmacokinetic studies found no difference in achievable serum levels with oral, compared to intraperitoneal, administration of calcitriol (61) or 1 α-hydroxycholecalciferol (62). Initial experience with doxercalciferol also appears promising (63). An oral derivative of paricalcitol is in development and an initial study in PD patients demonstrated efficacy (64).…”

Section: Vitamin Dmentioning

confidence: 99%

Management of Renal Osteodystrophy in Peritoneal Dialysis Patients

Moe

2004

Perit Dial Int

View full text Add to dashboard Cite

The term “renal osteodystrophy” encompasses all forms of metabolic bone disease found in dialysis patients. The primary approach to the treatment of renal osteodystrophy in peritoneal dialysis (PD) patients is similar to that in hemodialysis patients. However, the increased prevalence of adynamic bone histology, together with the difficulty in judging calcium balance, the inability to practicably give intravenous vitamin D, and the clearance of vitamin D and parathyroid hormone via dialysate require a different therapeutic approach in PD compared to hemodialysis patients. Clearly, more comparative studies of new agents are needed to find the optimal approach to achieving the K/DOQI guidelines in PD patients. The unique aspects of the approach to renal osteodystrophy in PD patients are the focus of this review.

show abstract

Section: Vitamin Dmentioning

confidence: 99%